Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. July 26, 2018. Sean Boyd.

Executive Summary

US FDA's Sean Boyd wants device-makers to provide the agency with clear, well-organized responses if they're hit with observations following a facility inspection. See what he said about it here.

"Your responses should enable the reviewer or the compliance officer to locate the evidence or the exhibits that you're providing to us that show what corrections you've made, what additional steps need to be taken and what timeline that will be taken on. So, providing even a simple outline or an index that points to exactly where we can find the answer to the question, or the solution to the problem identified, would really help facilitate our reviews." –Sean Boyd, deputy director for regulatory affairs for the Office of Compliance, US FDA's Center for Devices and Radiological Health

Click here for a free trial of Medtech Insight


Related Content

Compliance Corner: FDA's Boyd Gives 4 Pointers For Engaging With The Agency Post-Inspection





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts